Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin in Previously Treated Systemic Lupus Erythematosus
NCT07844200Phase 2Not yet recruiting
- Sponsor
- Medical Association for the Study of Cancer Biology and Treatment
- Start
- Feb 2027
- Primary completion
- Feb 2030
01
Overview
A Phase 2 trial of belantamab mafodotin in systemic lupus erythematosus (SLE), sponsored by Medical Association for the Study of Cancer Biology and Treatment. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07844200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07844200.